CHLOROPTIC S.O.P.
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHLOROPTIC S.O.P. (CHLOROPTIC S.O.P.).
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
| Metabolism | Primarily hepatic via glucuronidation; minor metabolism by reduction to aryl amines. |
| Excretion | Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%) |
| Half-life | Terminal half-life approximately 4-6 hours; clinical context: dosing every 4-6 hours for ocular infections |
| Protein binding | 15-20% bound to plasma proteins (albumin) |
| Volume of Distribution | 0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid |
| Bioavailability | Topical ophthalmic: low systemic absorption (<5%); oral: 30-50% |
| Onset of Action | Topical ophthalmic: 30 minutes to 1 hour |
| Duration of Action | Topical ophthalmic: 4-6 hours; sustained release formulation provides coverage for up to 12 hours |
| Molecular Weight | 323.13 |
Apply 0.5-inch ribbon into the conjunctival sac(s) 1-2 times daily, or more frequently as directed.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy not established; use only if potential benefit outweighs risk. |
| Geriatric use | Use with caution in elderly patients due to increased risk of adverse effects; monitor intraocular pressure. |
| 1st trimester | Avoid unless clearly needed. No well-controlled studies in pregnant women. Animal studies have shown adverse effects on fetal development at high doses. Chloramphenicol crosses the placenta and may cause gray baby syndrome. |
| 2nd trimester | Avoid unless clearly needed. Potential risk of gray baby syndrome and bone marrow suppression in the fetus. |
| 3rd trimester | Avoid near term due to risk of gray baby syndrome in the neonate. Chloramphenicol can accumulate in fetal tissues and cause cardiovascular collapse. |
Clinical note
Comprehensive clinical and safety monograph for CHLOROPTIC S.O.P. (CHLOROPTIC S.O.P.).
| Placental transfer | Chloramphenicol readily crosses the placenta, achieving fetal serum concentrations 30-80% of maternal levels. |
| Breastfeeding | Chloramphenicol is excreted in breast milk in low concentrations. However, there is a potential risk of bone marrow suppression and idiosyncratic aplastic anemia in nursing infants. The manufacturer recommends discontinuing nursing or the drug due to the potential for serious adverse reactions. |
■ FDA Black Box Warning
Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia) have been reported after topical ophthalmic use.
| Serious Effects |
Hypersensitivity to chloramphenicol or any component of the formulationHistory of chloramphenicol-associated bone marrow suppressionTreatment of trivial infections or prophylaxis
| Precautions | Bone marrow suppression including aplastic anemia; avoid prolonged use; monitor blood counts if used systemically; risk of superinfection; not for viral or fungal infections. |
| Food/Dietary | No known food interactions with ophthalmic chloramphenicol. No dietary restrictions are required during use. |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | Chloroptic S.O.P. contains chloramphenicol, which crosses the placenta. First trimester: minimal data, but theoretical risk of gray baby syndrome. Second and third trimesters: associated with gray baby syndrome in neonates if administered near term due to immature hepatic glucuronidation; avoid use in pregnancy unless no alternative. |
| Fetal Monitoring | Monitor maternal complete blood count (CBC) weekly due to risk of aplastic anemia. Fetal monitoring not typically required unless maternal systemic toxicity occurs. Assess neonatal CBC and bilirubin if maternal use near delivery. |
| Fertility Effects | No known effects on fertility based on available data. Animal studies not reported for ophthalmic formulation. |
| Clinical Pearls |
| CHLOROPTIC S.O.P. contains chloramphenicol, a bacteriostatic antibiotic effective against a wide range of ocular pathogens. Avoid use in patients with a history of bone marrow suppression or previous chloramphenicol-associated aplastic anemia. Prolonged use may lead to superinfection or ocular fungal infections. Monitor for signs of hypersensitivity such as conjunctival injection or eyelid edema. This formulation is a sterile ophthalmic ointment; apply a small ribbon to the lower conjunctival sac. Avoid contamination of the tube tip. |
| Patient Advice | Wash hands before and after application. · Tilt head back and pull down lower eyelid to create a small pocket. · Apply a small amount (about 1/2 inch) of ointment into the pocket. · Close eyes gently for 1-2 minutes to allow absorption. · Do not touch the tube tip to any surface, including the eye. · Temporary blurring may occur; avoid driving or operating machinery until vision clears. · Use for the full prescribed duration even if symptoms improve. · Report any unusual bleeding, bruising, or signs of infection to your doctor. · Store at room temperature away from moisture and heat. · Do not share this medication with others. |